Whether Detection of Gene Mutations Could Identify Low- or High-Risk Papillary Thyroid Microcarcinoma? Data from 393 Cases Using the Next-Generation Sequencing
Table 7
Multinomial logistic regression analysis to evaluate the association between the presence of BRAFV600E and patient characteristics of PTMC.
Independent variable
OR
CI 95%
Gender
F
1
—
Ref.
M
1.49
0.66–3.37
0.324
Age at diagnosis (years)
≤40
0.46
0.07–3.00
0.455
(40, 60]
0.24
0.04–1.46
0.089
>60
1
—
Ref.
Maximum tumor size (mm)
≤5
1
—
Ref.
>5
4.92
2.40-10.07
<0.001
Chronic lymphocytic thyroiditis
No
1
—
Ref.
Yes
0.7
0.31–1.60
0.401
Bilateralism
No
1
—
Ref.
Yes
0.6
0.19–1.90
0.686
Multifocality
No
1
—
Ref.
Yes
5.12
1.48-17.70
0.996
Intrathyroid spread
No
1
—
Ref.
Yes
1.02
0.10-10.25
0.67
Extrathyroidal extension
No
1
—
Ref.
Yes
2.39
0.73–7.78
0.749
Lymph node metastases
No
1
—
Ref.
Central compartment
2.53
0.78–8.21
0.481
Laterocervical compartment
8
0.65–98.99
0.627
Central +
2.9
0.54-15.57
0.985
Laterocervical compartment
≤5
1
—
Ref.
>5
0.85
0.23–3.09
0.625
Staging (VIII ed. TNM)
I
1
—
Ref.
II
3.68
0.54-25.15
0.256
Tumor recurrence
Yes
0.66
0.51–8.60
0.877
No
1
—
Ref.
n.a.
0.03
0.00–0.59
0.048
na: not available and PTMC: papillary thyroid microcarcinoma. Significant differences are shown in bold characters .